Back to Search
Start Over
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
- Source :
-
Integrative cancer therapies [Integr Cancer Ther] 2011 Jun; Vol. 10 (2), pp. 127-37. Date of Electronic Publication: 2010 Dec 08. - Publication Year :
- 2011
-
Abstract
- Background: Targeted therapy (TT), chemotherapy, and traditional Chinese medicine herbal treatment (TCM) can improve the prognosis of advanced pulmonary adenocarcinoma patients. Their independent prognostic value is unknown.<br />Objective: To study whether TCM improves survival in stage IV pulmonary adenocarcinoma patients with platinum-based chemotherapy (PBT), or combined PBT and second-line TT.<br />Methods: Retrospective analysis of 133 fully ambulant clinical outpatients treated with PBT alone or PBT with/without second-line TT, with/without TCM. Univariate (Kaplan-Meier) and multivariable (Cox model) survival analysis were performed, using disease-specific mortality as an endpoint.<br />Results: Gender (P = .002), TT (P < .0001), and TCM (P < .0001) had univariate prognostic value but not age, radiotherapy, or TCM syndrome differentiation (P > .10). TCM herbal treatment (P < .0001) and TT (P = .03) had multivariable independent prognostic value. TCM-treated patients (n = 103, PBT+TT+TCM+ = 62; PBT+TT-TCM+ =41) had 88% 1-year overall survival rate with median survival time (MST) of 27 months, contrasting 27% 1-year overall survival and MST of 5.0 months for non-TCM-treated (n = 30) patients. Patients with chemotherapy/TT/TCM (PBT+TT+TCM+, n = 62), TCM without TT (PBT+TT-TCM+, n = 41), or chemotherapy only (PBT+TT-TCM-, n = 30), had 1-year survival rates of 94%, 78%, and 27% respectively; for these 3 groups, respectively, MST was not reached (MST of 30.9 months), 22.6, and 5.0 months (P < .0001).<br />Conclusions: TCM herbal treatment may improve survival of stage IV pulmonary adenocarcinoma patients treated with chemotherapy without or with second-line TT. This warrants formal phase 1 and 2 trials and ultimately properly designed prospective clinical validation trials with adequate methodology developed for data collection.
- Subjects :
- Adenocarcinoma diagnosis
Adenocarcinoma radiotherapy
Adenocarcinoma of Lung
Adult
Aged
Aged, 80 and over
Antineoplastic Agents therapeutic use
Carboplatin therapeutic use
Cisplatin therapeutic use
Combined Modality Therapy methods
Deoxycytidine analogs & derivatives
Deoxycytidine therapeutic use
Docetaxel
Drug Therapy, Combination methods
Erlotinib Hydrochloride
Female
Gefitinib
Humans
Lung Neoplasms diagnosis
Lung Neoplasms radiotherapy
Male
Medicine, Chinese Traditional methods
Middle Aged
Neoplasm Staging
Outpatients
Paclitaxel therapeutic use
Prognosis
Quinazolines therapeutic use
Retrospective Studies
Survival Analysis
Taxoids therapeutic use
Treatment Outcome
Vinblastine analogs & derivatives
Vinblastine therapeutic use
Vinorelbine
Gemcitabine
Adenocarcinoma drug therapy
Adenocarcinoma pathology
Drugs, Chinese Herbal therapeutic use
Lung Neoplasms drug therapy
Lung Neoplasms pathology
Molecular Targeted Therapy methods
Organoplatinum Compounds therapeutic use
Platinum Compounds therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1552-695X
- Volume :
- 10
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Integrative cancer therapies
- Publication Type :
- Academic Journal
- Accession number :
- 21147812
- Full Text :
- https://doi.org/10.1177/1534735410387599